JP2021525731A - 多重特異性結合タンパク質及びその改善 - Google Patents

多重特異性結合タンパク質及びその改善 Download PDF

Info

Publication number
JP2021525731A
JP2021525731A JP2020566664A JP2020566664A JP2021525731A JP 2021525731 A JP2021525731 A JP 2021525731A JP 2020566664 A JP2020566664 A JP 2020566664A JP 2020566664 A JP2020566664 A JP 2020566664A JP 2021525731 A JP2021525731 A JP 2021525731A
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable domain
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525731A5 (cg-RX-API-DMAC7.html
Inventor
グレゴリー ピー. チャン,
グレゴリー ピー. チャン,
アン エフ. チュン,
アン エフ. チュン,
ジンヤン ドゥ,
ジンヤン ドゥ,
ダニエル ファロン,
ダニエル ファロン,
アシャ グリンバーグ,
アシャ グリンバーグ,
ウィリアム ヘイニー,
ウィリアム ヘイニー,
スティーブン オニール,
スティーブン オニール,
ロニー ウェイ,
ロニー ウェイ,
ブラッドリー エム. ランディ,
ブラッドリー エム. ランディ,
ビアンカ プリンツ,
ビアンカ プリンツ,
Original Assignee
ドラゴンフライ セラピューティクス, インコーポレイテッド
ドラゴンフライ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドラゴンフライ セラピューティクス, インコーポレイテッド, ドラゴンフライ セラピューティクス, インコーポレイテッド filed Critical ドラゴンフライ セラピューティクス, インコーポレイテッド
Publication of JP2021525731A publication Critical patent/JP2021525731A/ja
Publication of JP2021525731A5 publication Critical patent/JP2021525731A5/ja
Priority to JP2023201568A priority Critical patent/JP7726967B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020566664A 2018-05-28 2019-05-28 多重特異性結合タンパク質及びその改善 Pending JP2021525731A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023201568A JP7726967B2 (ja) 2018-05-28 2023-11-29 多重特異性結合タンパク質及びその改善

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677137P 2018-05-28 2018-05-28
US62/677,137 2018-05-28
PCT/US2019/034186 WO2019231920A1 (en) 2018-05-28 2019-05-28 Multi-specific binding proteins and improvements thereon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023201568A Division JP7726967B2 (ja) 2018-05-28 2023-11-29 多重特異性結合タンパク質及びその改善

Publications (2)

Publication Number Publication Date
JP2021525731A true JP2021525731A (ja) 2021-09-27
JP2021525731A5 JP2021525731A5 (cg-RX-API-DMAC7.html) 2022-06-07

Family

ID=68697331

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566664A Pending JP2021525731A (ja) 2018-05-28 2019-05-28 多重特異性結合タンパク質及びその改善
JP2023201568A Active JP7726967B2 (ja) 2018-05-28 2023-11-29 多重特異性結合タンパク質及びその改善

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023201568A Active JP7726967B2 (ja) 2018-05-28 2023-11-29 多重特異性結合タンパク質及びその改善

Country Status (15)

Country Link
US (1) US20210214436A1 (cg-RX-API-DMAC7.html)
EP (2) EP3802581A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021525731A (cg-RX-API-DMAC7.html)
KR (1) KR20210013160A (cg-RX-API-DMAC7.html)
CN (2) CN112533944A (cg-RX-API-DMAC7.html)
AU (1) AU2019277138B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020024235A2 (cg-RX-API-DMAC7.html)
CA (1) CA3101604A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003071A1 (cg-RX-API-DMAC7.html)
EA (2) EA202091977A1 (cg-RX-API-DMAC7.html)
IL (1) IL278943A (cg-RX-API-DMAC7.html)
MX (1) MX2020012905A (cg-RX-API-DMAC7.html)
PE (1) PE20210167A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202011763YA (cg-RX-API-DMAC7.html)
WO (1) WO2019231920A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016230828B2 (en) * 2015-03-10 2020-10-22 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) * 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
WO2020033702A1 (en) * 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
LT4279082T (lt) * 2019-01-17 2026-05-11 Immunocore Limited Farmacinės kompozicijos
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20230242647A1 (en) * 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CN113754771A (zh) * 2020-06-02 2021-12-07 三生国健药业(上海)股份有限公司 一种抗pdl1×egfr的双特异性抗体
EP4225792A1 (en) * 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
TWI825544B (zh) * 2020-12-31 2023-12-11 大陸商信達生物製藥(蘇州)有限公司 含異二聚體抗體Fc的蛋白以及其製備方法
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
AU2022246607A1 (en) * 2021-03-31 2023-11-16 Janssen Biotech, Inc. Materials and methods for immune effector cells redirection
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118475601A (zh) * 2022-01-05 2024-08-09 苏州系统医学研究所 一种t细胞受体及其制备方法和用途
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
KR20260051102A (ko) * 2023-07-07 2026-04-15 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Egfr/c-met 이중특이적 결합 단백질 및 이의 용도
AU2024334818A1 (en) * 2023-08-30 2026-03-19 Mink Therapeutics, Inc. Novel t cell receptors that bind to preferentially expressed antigen in melanoma (prame) and methods of use thereof
WO2025233431A1 (en) * 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025247255A1 (zh) * 2024-05-28 2025-12-04 映恩生物科技(上海)有限公司 一种抗dll3抗体、抗体药物偶联物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015537034A (ja) * 2012-11-21 2015-12-24 ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. 二重特異性抗体
JP2016506377A (ja) * 2012-11-27 2016-03-03 アジュ ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーションAjou University Industry−Academiccooperation Foundation 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するch3ドメイン変異体対、その作製方法および用途
JP2016514463A (ja) * 2013-03-15 2016-05-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
EP1809669A2 (en) * 2004-10-01 2007-07-25 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
WO2016087416A1 (en) * 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
EP3095792A1 (en) * 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
JP6840682B2 (ja) * 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的抗原結合タンパク質
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CN110944651A (zh) * 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
AU2018219348A1 (en) * 2017-02-10 2019-08-29 Dragonfly Therapeutics, Inc. Proteins binding BCMA, NKG2D and CD16
EP4273258A3 (en) * 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
AU2018220734B2 (en) * 2017-02-20 2025-03-06 Dragonfly Therapeutics, Inc. Proteins binding CD33, NKG2D and CD16
KR20210029298A (ko) * 2017-08-16 2021-03-15 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
RU2021110369A (ru) * 2017-09-07 2021-06-01 Драгонфлай Терапьютикс, Инк. Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
CN112119093A (zh) * 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EA202091976A1 (ru) * 2018-02-20 2021-07-06 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на cd33, и их применение

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015537034A (ja) * 2012-11-21 2015-12-24 ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. 二重特異性抗体
JP2016506377A (ja) * 2012-11-27 2016-03-03 アジュ ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーションAjou University Industry−Academiccooperation Foundation 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するch3ドメイン変異体対、その作製方法および用途
JP2016514463A (ja) * 2013-03-15 2016-05-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof

Also Published As

Publication number Publication date
US20210214436A1 (en) 2021-07-15
EP4537904A3 (en) 2025-07-16
JP7726967B2 (ja) 2025-08-20
BR112020024235A2 (pt) 2021-05-04
CN112533944A (zh) 2021-03-19
SG11202011763YA (en) 2020-12-30
EP3802581A4 (en) 2022-04-13
PE20210167A1 (es) 2021-01-28
EA202091977A1 (ru) 2021-02-09
CL2020003071A1 (es) 2021-05-24
CN117964773A (zh) 2024-05-03
EP3802581A1 (en) 2021-04-14
KR20210013160A (ko) 2021-02-03
AU2019277138A1 (en) 2020-12-17
WO2019231920A1 (en) 2019-12-05
AU2019277138B2 (en) 2024-06-13
MX2020012905A (es) 2021-05-27
IL278943A (en) 2021-01-31
EA202092907A1 (ru) 2021-04-13
JP2024023438A (ja) 2024-02-21
EP4537904A2 (en) 2025-04-16
CA3101604A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
JP7726967B2 (ja) 多重特異性結合タンパク質及びその改善
ES2986967T3 (es) Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
ES2954851T3 (es) Proteínas de unión multiespecífica que se unen a HER2, NKG2D y CD16, y métodos de uso
US20210261668A1 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
JP2022101687A (ja) Her2、NKG2DおよびCD16に結合するタンパク質
JP2022101709A (ja) ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
JP2021035388A (ja) Caix、ano1、メソテリン、trop2、ceaまたはクローディン−18.2を標的にする多重特異性結合タンパク質
US20200095327A1 (en) Antibody heavy chain variable domains targeting the nkg2d receptor
JP2021098733A (ja) Nkg2d、cd16および腫瘍関連抗原に結合するタンパク質
JP2021512914A (ja) ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
JP2022105121A (ja) Psma、nkg2dおよびcd16に結合するタンパク質
CN111432832A (zh) 结合nkg2d、cd16和c-型凝集素样分子-1(cll-1)的蛋白质
CN110573530A (zh) 结合cd33、nkg2d和cd16的蛋白
JP2020507328A (ja) Bcma、nkg2d及びcd16と結合するタンパク質
CN111278455A (zh) 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
BR112020003654A2 (pt) proteínas de ligação ao nkg2d, cd16 e a um antígeno associado a tumor
CN112823022A (zh) 结合bcma、nkg2d和cd16的多特异性结合蛋白以及使用方法
JP2020510644A (ja) Gd2、nkg2dおよびcd16に結合するタンパク質
JP2020508998A (ja) Cd123、nkg2dおよびcd16に結合するタンパク質
JP2021523140A (ja) Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質
WO2024199458A1 (en) Il-2 variants with improved stability and compositions thereof
RU2816716C2 (ru) Белки, связывающие NKG2D, CD16 и опухолеассоциированный антиген
RU2820603C2 (ru) Белки, связывающие cd33, nkg2d и cd16
EA046081B1 (ru) Мультиспецифические связывающие белки и их усовершенствования

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206